Synonyms: Superdrol, Methasterone, M-Drol, S-Drol, Methastadrol.
Chemical Formula: C21H34O2
Molecular Weight: 318
Q Qatio: 20
Anabolic #: 400
Androgenic #: 20
Oral Bioavailability: Estimated at 50%
AR Binding Affinity: NA
SHBG Binding Affinity: High
Half Life: ~8 hours
5-10mg/day when stacked
Average Cycle Length: 2-4 weeks
Methyldrostanolone is a C-17 alpha alkylated steroid, originally developed by the American pharmaceutical company Syntex. This steroid is already active and does not require conversion. Methyldrostanolone is the 17aa version of the injectable steroid drostanolone (Masteron). This extra methylation makes this steroid about 3-4x more anabolic than Masteron, and slightly more anabolic than oxandrolone (Anavar). Due to the dimethylation, the toxicity of methyldrostanolone is greater than most other oral steroids. There have been many reported cases of heptatoxicity with this compound. (1-3)
Despite the fact that methyldrostanolone is a DHT derivative and cannot convert to estrogen, some users have still reported gyno like symptoms during or after a cycle. This effect is likely related to the strong SHBG binding effect and increase in freely circulating estrogen (and testosterone) from SHBG. Gyno symptoms may also be related to the fact that methldrostanolone lacks a strong DHT metabolite to antagonize the effects of estrogen (while also having a relatively low intrinsic androgenic value).
Having a fairly low androgenic value will mean that methyldrostanolone will be light on the hairline for most men. However those susceptible to male pattern baldness may still noticed accelerated hair loss during a cycle.
Because of the di-methylation, methlydrostanolone is considerably more resistant to breakdown, thus more potent per mg than most other steroids. However this makes it more liver toxic than other single methylated 17aa orals. Negative effects on the liver generally manifest as a condition known as reversible cholestasis. This is essentially a slowing or complete blockage of bile acids from the liver. Immediate signs of compromised liver function included reduced appetite and general sickness, which will soon be accompanied by yellowing of the eyes (jaundice), excessive itchiness and very dark urine. If these effects are noticed, methyldrostanolone should be discontinued immediately.
Because the effects on the liver it is very important to use a liver protecting supplement during any methyldrostanolone cycle. If not using a supplement to protect your liver, methyldrostanolone should never be used any longer than 2 weeks, with a maximum cycle length of 4 weeks with liver protection.
Other reversible side effects from methyldrostanolone may include increased blood pressure, reduced HDL cholesterol and lower back pumps.
Results wise, users should expect extreme strength increases and weight gain in a relatively short 2-4 week period. Weight gain upwards of 20lbs in 4 weeks is not unheard of with this incredibly potent compound. Although subcutaneous water gain would be minimal, intramuscular water retention should be expected. This is due to inhibition of 11b-hydroxylase and build-up of mineralcorticoids which encourage salt and water retention within the muscles. The most obvious physical effects will be improved vascularity, aggressive muscular pumps, and oily skin.
While methyldrostanolone can stack well with most other steroids, it should never be stacked with another methylated (17aa) steroid.
Products With This Compound:
Cholestatic Jaundice and IgA Nephropathy Induced by OTC Muscle Building Agent Superdrol.
Beata Jasiurkowski MD, et al.
The American Journal of Gastroenterology (2006) 101, 2659-2662;
Severe Cholestasis and Renal Failure Associated with the Use of the Designer Steroid Superdrol (Methasteron): A Case Report and Literature Review
John Nasr and Jawad Ahmad
Digestive Diseases and Sciences
Methasteron-Associated Cholestatic Liver Injury: Clinicopathologic Findings in 5 Cases”
Neeral L. et al.
Clinical Gastroenterology and Hepatology, Volume 6, Issue 2, February 2008, Pages 255-258
Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes”
Julie Gauthier, Danielle Goudreault, Donald Poirier and Christiane Ayotte
Steroids; Volume 74, Issue 3, March 2009, Pages 306-314